IMUNON Reports Phase 2 Data Showing Improved Survival in Advanced Ovarian Cancer
IMUNON reports updated Phase 2 data showing improved Overall Survival (OS) with IMNN-001 in advanced ovarian cancer.
Oncology Clinical Trials | 26/03/2026 | By News Bureau
MMS Holdings (MMS) has been selected by Friends of Cancer Research (Friends) to support the development of practical decision frameworks to inform the interpretation of interim overall survival (OS) data in oncology clinical trials.
Oncology Clinical Trials | 20/08/2025 | By Dineshwori | 196
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy